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Dear Readers
It is our great pleasure to welcome you to Drugs: Real
World Outcomes, the latest offering from Adis that targets
research involving the use of real-world data. We all know
that the gold standard in research is the randomized con-
trolled clinical trial; however, we all also know that these
trials by the nature of their design fail to inform clinicians
on many fronts. While they provide vital confirmation of
efficacy and safety, they exclude many relevant patient
groups, such as the elderly, children and those with co-
morbidities, and they are conducted in ideal settings, with
an expectation of high adherence rates. Clinicians need to
know how their patients will respond to a drug in real life—
and the potential impact of factors such as race, age, sex, co-
morbidities, performance status and other medications.
Drugs: Real World Outcomes aims to provide a vehicle
for dissemination and a forum for discussion of information
about how drugs perform in daily clinical practice. We will
include both original research and definitive reviews on the
use of real-world data to help you evaluate health outcomes
and make informed healthcare decisions on drugs, devices
and other interventions.
Adis has been publishing high quality journals for over
40 years, with experience in the areas of drug treatment,
drug safety, pharmacokinetics, pharmacoeconomics and
molecular diagnostics amongst others, and has a current
portfolio of more than 30 journals. Drugs was first pub-
lished in 1971 and has developed a reputation as the go-to
source of information on drug treatment and drug evalua-
tion. Over the years, the family of Drugs has grown to
include Drug Safety, Drugs & Aging, BioDrugs, Pediatric
Drugs and Drugs in R&D. With Drugs: Real World Out-
comes, we now apply our knowledge and experience to
bring you investigations on drug utilization, patterns of
prescribing, pharmacovigilance, treatment guideline
adherence, benefit-risk assessments, comparative effec-
tiveness and economic analyses.
The journal will be published online only and will be
entirely open access. Now that the Adis portfolio of jour-
nals has been successfully integrated into the production
systems and online platforms provided by Springer, as an
Adis Open journal we can offer authors
• Efficient article submission, peer review and tracking
processes
• Expedited publication timelines
• High visibility thanks to unrestricted online access
• Easy discoverability and access for readers to their
work
• Citation tracking and inclusion in bibliographic
databases
Additional benefits of being a part of Springer include
the availability of innovative online features for every
article via SpringerLink.
We are excited about the contribution the journal will be
able to make to clinical practice by providing meaningful
information for critical decision making. We welcome pre-
submission enquiries, and look forward to working with
you on Drugs: Real World Outcomes.
Dene C. Peters and Anton van Rensburg, Editors
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